New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
08:38 EDTNVS, ENTAEnanta's HCV NS5A inhibitor EDP-239 advances into combination studies
Enanta Pharmaceuticals (ENTA) announced that Novartis has advanced EDP-239, Enanta’s NS5A inhibitor for hepatitis C virus, into drug combination studies with alisporivir, a cyclophilin inhibitor being developed by Novartis (NVS). These combination studies are part of Enanta’s existing collaboration with Novartis for the development of new combination therapies for the treatment of HCV using Enanta’s NS5A inhibitors. The phase 1 combination study conducted by Novartis is investigating the pharmacokinetics, safety, and tolerability of alisporivir and EDP-239 when co-administered to healthy adult subjects and is scheduled to enroll 42 healthy subjects.
News For ENTA;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
17:51 EDTNVSFDA approves first seasonal influenza vaccine containing an adjuvant
The U.S. FDA approved Fluad, the first seasonal influenza vaccine containing an adjuvant. Fluad, a trivalent vaccine produced from three influenza virus strains (two subtype A and one type B), is approved for the prevention of seasonal influenza in people 65 years of age and older. Fluad and Agriflu are manufactured by Novartis Vaccines and Diagnostics Limited, an affiliate of Novartis Vaccines and Diagnostics, based in Cambridge, Massachusetts. Reference Link
10:06 EDTNVSHigh option volume stocks
High option volume stocks: BDBD UNXL NVS SEDG BLOX GPRE SIG BPL TIF DY
05:25 EDTNVSNovartis receives EU approval for Entresto
Novartis announced that the European Commission has approved Entresto for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction. Entresto is a twice a day tablet and has a unique mode of action which is thought to reduce the strain on the failing heart.
November 23, 2015
16:06 EDTENTAEnanta reports Q4 EPS 29c, consensus 15c
Subscribe for More Information
15:28 EDTENTANotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Palo Alto (PANW), consensus 32c... Copart (CPRT), consensus 43c... Brocade (BRCD), consensus 24c... Post Holdings (POST), consensus 29c... YY (YY), consensus 82c... Dycom (DY), consensus $1.01... Cubic (CUB), consensus 96c... Enanta (ENTA), consensus 15c.
05:37 EDTNVSNovartis receives two EU approvals for Cosentyx
Novartis announced today that the European Commission has approved Cosentyx for the treatment of people living with ankylosing spondylitis, or AS, and psoriatic arthritis, or PsA. For AS, this is the first new treatment advance in 16 years since the development of the current standard of care, anti-tumor necrosis factor, or anti-TNF, therapy. Cosentyx is the first in a new class of medicines called interleukin-17A, or IL-17A, inhibitors to be made available in Europe for AS and PsA. These approvals follow on from the earlier EC approval of Cosentyx for the first-line treatment of patients with moderate-to-severe plaque psoriasis. AS and PsA are common inflammatory joint conditions affecting approximately five million people in Europe, yet they remain significantly under-diagnosed and under-treated. If not treated effectively, they can lead to irreversible damage to the spine and joints, causing life-long pain and disability. New treatments are urgently needed for both conditions as many patients do not respond well to existing treatments, with up to 40% not responding sufficiently to anti-TNFs.
November 20, 2015
17:16 EDTNVSNovartis announces FDA approval of Tafinlar + Mekinist
Subscribe for More Information
14:41 EDTNVSNY AG leads team of states in $390M settlement with Novartis over kickbacks
Subscribe for More Information
14:00 EDTNVSNY AG leads team of states in $390M settlement with Novartis over kickbacks
Subscribe for More Information
10:52 EDTNVSFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information
November 18, 2015
08:11 EDTNVSIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
07:43 EDTNVSJefferies to hold a conference
Subscribe for More Information
November 17, 2015
16:38 EDTNVSAduro Biotech to delay filing 10-Q
Subscribe for More Information
07:34 EDTNVSOphthotech to hold a conference call
Subscribe for More Information
06:08 EDTNVSRoche subsidiary to participate in Ophthotech and Novartis agreement
Subscribe for More Information
05:24 EDTNVSNovartis announces Phase III FLAME head-to-head trial met primary endpoint
Subscribe for More Information
November 16, 2015
09:11 EDTENTAEnanta says ABT-493 study data show 'high sustained' response rates
Enanta Pharmaceuticals announced data from AbbVie's SURVEYOR studies of its investigational treatment regimen, consisting of ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, that show high rates of sustained virologic response at 12 weeks post-treatment in non-cirrhotic patients with chronic hepatitis C virus infection. After 12 weeks of treatment, SVR12 rates achieved were 97%-100% in genotype 1 patients, 96-100 percent in genotype 2, and 83%-94% in genotype 3. These data will be presented at The Liver Meeting, which is the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco. Separately, in a late-breaking presentation of the SURVEYOR-1 trial, additional data will show non-cirrhotic GT1 chronic HCV patients who received a shorter duration of treatment for 8 weeks with ABT-493 and ABT-530 achieved a SVR rate of 97%.
November 15, 2015
14:30 EDTENTAEnanta confirms interim Phase 3b data on Viekira Pak
Subscribe for More Information
November 13, 2015
08:28 EDTENTAAmerican Association for Study of Liver Diseases to hold annual meeting
The Liver Meeting 2015 is being held in San Francisco on November 13-17.
November 11, 2015
07:56 EDTNVSBoston Biotech Conferences to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use